An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate

BACKGROUND AND PURPOSE: Combretastatin A-4 3-O-phosphate (CA4P) is in clinical trial as a tumour vascular disrupting agent (VDA) but the cause of blood flow disruption is unclear. We tested the hypothesis that activation of Rho/Rho kinase (ROCK) is fundamental to the effects of this drug in vivo. EX...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Pharmacol
Hlavní autoři: Williams, L J, Mukherjee, D, Fisher, M, Reyes-Aldasoro, C C, Akerman, S, Kanthou, C, Tozer, G M
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
Research Papers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4294113/
https://ncbi.nlm.nih.gov/pubmed/24930520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12817
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky